AI-Driven probes Gator Bio recently launched Gator HIS XT probes featuring AI-designed binding proteins, signaling an opportunity to sell AI-enhanced biosensing capabilities and related services to biotherapeutics developers seeking advanced assay performance.

Biolayer Interferometry Expansion With a mature BLI platform and 400+ installations, there is potential to upsell advanced biosensor options, extended regeneration cycles, and higher-throughput configurations to current customers and new biopharma clients pursuing rapid, reliable kinetics.

Strategic Partnerships Past and ongoing collaborations with Bristol-Myers Squibb, Genex India, Monod Bio, and regional distributors indicate a channel-rich growth path; leverage these relationships to expand regional footprints and cross-sell GeneSwift reagents, probes, and related services.

Genomic & Protein Tools Product launches around GeneSwift reagents and genome titer capabilities highlight cross-sell opportunities to genomic and proteomic workflows, including gene therapy and biotherapeutics programs that require robust biosensing integrations.

Global Market Potential The combination of a mid-sized company profile (51-200 employees), strong scientific support, and international partnerships suggests strategic targeting of mid-market biotechs and contract research organizations seeking cost-effective, reliable BLI solutions with AI-enabled assets.